Phase IV Commitments For Registries Likely To Increase, Genentech Says

Manufacturers should expect more postmarketing commitments for safety and pregnancy exposure registries for chronic disease medications, Genentech Senior Epidemiologist Haley Kaplowitz, PhD, said during the Drug Information Association conference on pharmacovigilance in Washington, D.C. Jan. 14